Entries by admin

ACHILLES FOUNDERS MAP TRUNCAL AND BRANCHED MUTATIONS

Achilles Founders map truncal and branched mutations and copy number events to predict early relapse in non-small cell cancer lungs, opening up significant new opportunities for clinical trial design and monitoring of patients A large scale Cancer Research UK study, TRACERx, which is led by the founders of Achilles, has found that unstable chromosomes within […]

ACHILLES THERAPEUTICS STARTS 2017 WITH MOVE TO STEVENAGE BIOSCIENCE CATALYST

Achilles Therapeutics starts 2017 with move to Stevenage Bioscience Catalyst Immunotherapy company joins growing cell & gene therapy community on campusStevenage, UK, January 4 2017 – Achilles Therapeutics, which is focused on the development of novel cancer immunotherapies targeting neoantigens, has moved into its new headquarters at Stevenage Bioscience Catalyst (SBC), the open innovation campus driving […]

ACHILLES THERAPEUTICS LAUNCHED WITH FUNDS OF £13.2 MILLION TO DEVELOP IMMUNOTHERAPIES FOR CANCER

ACHILLES THERAPEUTICS LAUNCHED WITH FUNDS OF £13.2 MILLION TO DEVELOP IMMUNOTHERAPIES FOR CANCER Wednesday 5 October, 2016 SYNCONA LLP and CANCER RESEARCH TECHNOLOGY (CRT) announce the formation of Achilles Therapeutics Ltd today (Wednesday). The new private company will bring together world-class research from UCL (University College London) and the Francis Crick Institute, funded by Cancer […]